Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Porter, Ross JohnAndrews, CarolineBrice, Daniel PaulDurum, Scott KennethMcLean, Mairi Hall2019-07-172019-07-172018-09-15Porter, R J, Andrews, C, Brice, D P, Durum, S K & McLean, M H 2018, 'Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?', Inflammatory Bowel Diseases, vol. 24, no. 10, pp. 2123-2134. https://doi.org/10.1093/ibd/izy2301078-0998ORCID: /0000-0002-7443-2653/work/94084011http://hdl.handle.net/2164/12590Drs. Andrews and Durum are supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, National Institutes of Health, USA.12641921engInflammatory Bowel Diseaseimmunoregulationcytokineulcerative colitisCrohn's diseasetreatmentR Medicine (General)R1Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?Journal item10.1093/ibd/izy2302410